Literature DB >> 34402459

Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration.

Stanley H Appel1, David R Beers, Weihua Zhao.   

Abstract

PURPOSE OF REVIEW: Neuroinflammation is an important mediator of the pathogenesis of disease in amyotrophic lateral sclerosis (ALS). Genetic mutations such as C9orf72 have begun to define the numerous cell autonomous pathways that initiate motor neuron injury. Yet, it is the signalling to surrounding glia and peripherally derived immune cells that initiates the noncell autonomous inflammatory process and promotes self-propagating motor neuron cell death. The purpose of this review is to explore the systemic immune/inflammatory contributions to the pathogenesis of ALS: what are the peripheral pro-inflammatory signatures, what initiates their presence and do they represent potential therapeutic targets. RECENT
FINDINGS: In ALS, motor neuron cell death is initiated by multiple cell autonomous pathways leading to misfolded proteins, oxidative stress, altered mitochondria, impaired autophagy and altered RNA metabolism, which collectively promote noncell autonomous inflammatory reactivity. The resulting disease is characterized by activated microglia and astrocytes as well as peripherally derived pro-inflammatory innate and adaptive immune cells. In this unrelenting disorder, circulating blood monocytes and natural killer cells are pro-inflammatory. Furthermore, regulatory T lymphocytes are dysfunctional, and pro-inflammatory cytokines and acute phase proteins are elevated.
SUMMARY: The collective dysregulation of cells and cytokines in patients with ALS accurately reflect increased disease burdens, more rapid progression rates and reduced survival times, reinforcing the concept of ALS as a disorder with extensive systemic pro-inflammatory responses. These increased systemic pro-inflammatory immune constituents provide potentially meaningful therapeutic targets.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34402459     DOI: 10.1097/WCO.0000000000000983

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  7 in total

1.  Integrative Profiling of Amyotrophic Lateral Sclerosis Lymphoblasts Identifies Unique Metabolic and Mitochondrial Disease Fingerprints.

Authors:  Teresa Cunha-Oliveira; Marcelo Carvalho; Vilma Sardão; Elisabete Ferreiro; Débora Mena; Francisco B Pereira; Fernanda Borges; Paulo J Oliveira; Filomena S G Silva
Journal:  Mol Neurobiol       Date:  2022-08-06       Impact factor: 5.682

2.  Clinical Course of Atopic Dermatitis in an Adult with Amyotrophic Lateral Sclerosis: Aetiological Implications of Voluntary Movements and Dermatitis Severity.

Authors:  Tatsushi Kiyohara; Takayasu Fukudome; Yoshiyuki Kamio; Yuta Koike; Hiroyuki Murota
Journal:  Acta Derm Venereol       Date:  2022-02-08       Impact factor: 3.875

3.  ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression.

Authors:  Hazel Quek; Carla Cuní-López; Romal Stewart; Tiziana Colletti; Antonietta Notaro; Tam Hong Nguyen; Yifan Sun; Christine C Guo; Michelle K Lupton; Tara L Roberts; Yi Chieh Lim; Lotta E Oikari; Vincenzo La Bella; Anthony R White
Journal:  J Neuroinflammation       Date:  2022-02-28       Impact factor: 9.587

4.  Clinical characteristics and prognosis of amyotrophic lateral sclerosis with autoimmune diseases.

Authors:  Jin-Yue Li; Xiao-Han Sun; Dong-Chao Shen; Xun-Zhe Yang; Ming-Sheng Liu; Li-Ying Cui
Journal:  PLoS One       Date:  2022-04-07       Impact factor: 3.240

5.  Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS.

Authors:  David R Beers; Jason R Thonhoff; Alireza Faridar; Aaron D Thome; Weihua Zhao; Shixiang Wen; Stanley H Appel
Journal:  Ann Neurol       Date:  2022-05-07       Impact factor: 11.274

6.  HPLC-MS/MS Oxylipin Analysis of Plasma from Amyotrophic Lateral Sclerosis Patients.

Authors:  Mauricio Mastrogiovanni; Andrés Trostchansky; Hugo Naya; Raúl Dominguez; Carla Marco; Mònica Povedano; Rubèn López-Vales; Homero Rubbo
Journal:  Biomedicines       Date:  2022-03-15

Review 7.  Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.

Authors:  David Reyes-Leiva; Oriol Dols-Icardo; Sonia Sirisi; Elena Cortés-Vicente; Janina Turon-Sans; Noemi de Luna; Rafael Blesa; Olivia Belbin; Victor Montal; Daniel Alcolea; Juan Fortea; Alberto Lleó; Ricard Rojas-García; Ignacio Illán-Gala
Journal:  Front Neurol       Date:  2022-01-18       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.